Komori
Treasury Stock4527ROHTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice Regarding the Repurchase of Treasury Shares

The Company has resolved to repurchase up to 1,500,000 common shares on the market, for a total purchase price of up to ¥3 billion. The acquisition period is from 27 March 2026 to 31 December 2026.

Worth reading
41Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
1500000
Shares
Wording
Definitive
How definitive the wording is.

Resolution on acquisition limit

Resolved 26 March 2026Market purchases on the Tokyo Stock Exchange
Total acquisition price¥3 billion (maximum)
Maximum number of shares to be acquired1,500,000 shares (maximum)The Company's common shares
0.66%Maximum number that can be acquired

The full horizontal line represents all issued shares, with marks at 10% intervals. The colored section represents the percentage stated in the resolution as the maximum proportion that may be repurchased under it.
This is a limit, and does not mean that the company will buy back all of it. The amount actually acquired will be shown in a later disclosure on the status of the acquisition of treasury shares.

Acquisition period

From 27 March 2026 to 31 December 2026

Reason for acquisition

The share buyback is being conducted to enable improvements in capital efficiency and the execution of agile capital policies.

Reference (number of shares stated in the document)
Current number of treasury shares10,213,970 shares (as of 26 March 2026; common shares)
Total number of issued shares236,178,310 shares (as of 26 March 2026, including treasury shares). The number of issued shares excluding treasury shares is 225,964,340.
Resolution on acquisition limit
ItemDetails
Class of shares to be acquiredThe Company's common shares
Maximum number of shares to be acquired1,500,000 shares (maximum)
Percentage of total issued shares0.66%
Total acquisition price¥3 billion (maximum)
Acquisition periodFrom 27 March 2026 to 31 December 2026
Method of acquisitionMarket purchases on the Tokyo Stock Exchange
Reason for acquisitionThe share buyback is being conducted to enable improvements in capital efficiency and the execution of agile capital policies.
Resolution date26 March 2026
Current number of treasury shares10,213,970 shares (as of 26 March 2026; common shares)
Total number of issued shares236,178,310 shares (as of 26 March 2026, including treasury shares). The number of issued shares excluding treasury shares is 225,964,340.
Items this document does not state (6)
Number of shares to be retiredPercentage of total issued shares before retirementScheduled retirement dateTotal number of issued shares after retirementChange in acquisition periodChange in acquisition limit

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The share buyback is being conducted to enable improvements in capital efficiency and the execution of agile capital policies.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Repurchase of Treasury Shares | ROHTO PHARMACEUTICAL CO.,LTD. (4527) timely disclosure | Komori